More about

Balloon Angioplasty

News
April 04, 2022
3 min read
Save

Chocolate Touch DCB successful in head-to-head trial in femoropopliteal disease

Chocolate Touch DCB successful in head-to-head trial in femoropopliteal disease

WASHINGTON — A new study supports the safety and effectiveness of the Chocolate Touch drug-coated balloon for the treatment of symptomatic peripheral arterial disease with lesions in superficial femoral and popliteal arteries.

News
February 08, 2022
2 min read
Save

DCB effective for PAD treatment at 5 years regardless of sex, diabetes status

DCB effective for PAD treatment at 5 years regardless of sex, diabetes status

In a real-world registry of patients with peripheral artery disease, 5-year outcomes of a drug-coated balloon were positive regardless of sex and diabetes status, researchers reported at the International Symposium on Endovascular Therapy.

News
February 03, 2022
2 min read
Save

Speaker: Time to ‘move on’ from mortality-related concerns of paclitaxel-coated devices

Speaker: Time to ‘move on’ from mortality-related concerns of paclitaxel-coated devices

Contemporary data suggest paclitaxel-coated devices do not elevate mortality risk in patients with peripheral artery disease, and they should be used more routinely, according to a speaker.

News
January 15, 2022
2 min read
Save

DCB may be noninferior to DES in setting of small-vessel CAD, regardless of PCI indication

DCB may be noninferior to DES in setting of small-vessel CAD, regardless of PCI indication

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

News
October 12, 2021
2 min read
Save

PCB outperforms PTA at 2 years, including in challenging patients with PAD

PCB outperforms PTA at 2 years, including in challenging patients with PAD

In patients with peripheral artery disease and femoropopliteal lesions, a low-dose paclitaxel-coated balloon enhanced patency and reduced risk for reintervention compared with percutaneous transluminal angioplasty, researchers reported.

News
October 08, 2021
2 min read
Save

DCB 5-year results in complex patients with PAD similar to overall cohort

DCB 5-year results in complex patients with PAD similar to overall cohort

In patients with complex peripheral artery disease, a drug-coated balloon performed similarly to how it did in the general PAD population, according to new data from the IN.PACT Global registry.

News
May 13, 2021
2 min read
Save

Low-dose paclitaxel-coated balloon noninferior to higher-dose PCB for treatment of PAD

Low-dose paclitaxel-coated balloon noninferior to higher-dose PCB for treatment of PAD

In a head-to-head trial, a low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon for treatment of patients with peripheral artery disease.

News
February 12, 2021
1 min read
Save

Two studies of PCB show no excess mortality signal at 5 years

Two studies of PCB show no excess mortality signal at 5 years

At 5 years, there was no link between a paclitaxel-coated balloon and excess mortality compared with percutaneous transluminal angioplasty in two studies of patients with peripheral artery disease.

News
January 29, 2021
2 min read
Save

DCBs with different paclitaxel doses similar in safety, efficacy at 2 years in PAD

DCBs with different paclitaxel doses similar in safety, efficacy at 2 years in PAD

A low-dose paclitaxel-coated balloon was similar to a higher-dose paclitaxel-coated balloon in safety and efficacy among patients with femoropopliteal lesions at 2 years, according to new data from the COMPARE trial.

News
November 09, 2020
2 min read
Save

Pooled analysis shows no 4-year mortality risk with low-dose PCB

Pooled analysis shows no 4-year mortality risk with low-dose PCB

In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat peripheral artery disease, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years.

View more